Post-earnings recap
Reported
Thu, Aug 8, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Amicus Therapeutics reported a loss per share of $0.36, which was slightly worse than expected. The stock fell by 3.72% following the earnings release, reflecting investor concerns about the lack of revenue information and forward guidance. The company's focus remains on its clinical trials, but the absence of specific future projections may lead to uncertainty among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | -2.59% |
| Revenue | N/A | N/A | N/A |
Management's tone was defensive, emphasizing the importance of ongoing projects. They did not provide specific guidance for future quarters.
Management did not provide specific guidance for future performance.
The company is focusing on its ongoing clinical trials and product development.